// App-Quantinova.ai

: Efficacy and safety of VR475 (budesonide suspension delivered by the VR475 Inhalation System) as add-on treatment in patients with severe asthma (CLEARCUT Study)

Researchers

Presenter

  • Tim Harrison

Principal Investigators

  • Julie Young

  • Alison Scrimgeour

  • Sally Du Toit

  • Raulin Surujbally

  • Gary Burgess

Medical Centers

  • Nottingham Trent University, Nottingham, United Kingdom

  • Vectura Ltd, Chippenham, United Kingdom.

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Budesonide

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Controlled

  • Parallel Group

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved